MIRA Pharmaceuticals Reports 2026 Annual Meeting Voting Results

What Happened
MIRA Pharmaceuticals, Inc. (MIRA) filed an 8-K disclosing the results of its 2026 Annual Meeting of Stockholders held on September 11, 2026. The record date was July 21, 2026, when 42,022,087 shares of common stock were outstanding. At the meeting 26,499,076 shares (about 63.06% of outstanding shares) were present or represented by proxy, constituting a quorum. Stockholders approved all three proposals: election of five directors, ratification of Salberg & Company, P.A. as independent registered public accounting firm for 2026, and approval to allow adjournment to solicit additional proxies if needed.

Key Details

• Record date/outstanding shares: July 21, 2026 — 42,022,087 shares outstanding.
• Shares present/represented: 26,499,076 (≈63.06% of outstanding).
• Directors elected (votes For / Votes Withheld / Broker non-votes):
  • Erez Aminov: 20,559,502 For; 226,540 Withheld; 5,713,034 broker non-votes.
  • Matthew Pratt Whalen: 20,560,180 For; 225,862 Withheld; 5,713,034 broker non-votes.
  • Matthew Del Giudice, M.D.: 20,558,412 For; 227,630 Withheld; 5,713,034 broker non-votes.
  • Denil Nanji Shekhat, M.D.: 20,138,206 For; 647,830 Withheld; 5,713,034 broker non-votes.
  • Edward MacPherson: 20,435,527 For; 350,515 Withheld; 5,713,034 broker non-votes.
• Auditor ratification (Proposal 2): Salberg & Company, P.A. approved — 25,950,852 For; 158,064 Against; 390,160 Abstained.
• Adjournment proposal (Proposal 3) approved — 24,897,741 For; 1,205,307 Against; 396,028 Abstained.

Why It Matters
The vote confirms the company’s board slate and the choice of independent auditor for the 2026 fiscal year, removing near-term governance uncertainty. The presence of roughly 5.7 million broker non-votes (shares present but not voted on director elections) is notable because those shares counted for quorum but did not affect director vote totals, which can influence close contests. Investors should view this as a routine corporate governance filing that documents board continuity and auditor ratification; no financial results or management changes were reported in this 8-K.